Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 9;11(6):e005898. doi: 10.1136/jitc-2022-005898

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Characteristics of patients with hematologic toxicities. (A) Bleeding manifestations of each patient who experienced clinically relevant bleeding after receiving CD22 CAR T-cell infusion. (*) Patients with carHLH. (B) Number of patients who experienced one clinically relevant toxicity of coagulopathy, carHLH or neurotoxicity and those that had more than one manifestation. Five of the 21 patients who did not experience coagulopathy, carHLH or neurotoxicity were unevaluable for coagulopathy, but presumed to not be coagulopathic. CAR, chimeric antigen receptor; carHLH, CAR-associated HLH-like toxicity; CRS, cytokine release syndrome; DAH, diffuse alveolar hemorrhage; HLH, hemophagocytic lymphohistiocytosis; ICH, intracranial hemorrhage; IV, intravenous line site.